Correlation Between Amyloid Reduction and Clinical Outcomes: Exploratory Analyses from the Gantenerumab Scarlet Road and Marguerite Road Open-Label Extension Studies

Paul Delmar1, Geoffrey A Kerchner1, Guoqiao Wang2, Randall Bateman2, Gregory Klein1, Mirjana Andjelkovic1, Danielle Abi-Saab4, Szofia Bullain4, Alonso Montoya3, Paulo Foutoura4, Rachelle Doody6

1Roche Pharma Research and Early Development; 2Washington University, School of Medicine, St. Louis, MO, USA; 3Roche/Genentech Product Development, Neuroscience, Basel, Switzerland; 4Roche Pharma Research and Early Development, Basel, Switzerland; 5Medical Strategy, Hoffmann-La Roche, Mississauga, ON; 6Genentech Inc., South San Francisco, CA, USA

Background/Objectives: Gantenerumab, a fully human monoclonal antibody, is under investigation as a disease-modifying treatment for Alzheimer’s disease (AD). In the ongoing SCarlet RoAD (SR [NCT01224106]) and Marguerite RoAD (MR [NCT02051608]) open-label extension (OLE) studies, patients with AD who received gantenerumab uptitrated to subcutaneous doses ≤1200 mg monthly for 2 years exhibited high levels of PET amyloid reduction, such that 52% of patients improved below the amyloid positivity threshold.(1) Here we explore the relationship between amyloid reduction and clinical outcomes during the MR and SR OLE studies

Methods: Amyloid PET reductions were quantified using a prespecified method(2) and centiloid transformation.(3) Clinical outcomes evaluated included CDR-SB, ADAS-COG11, and MMSE. The analysis included all currently available patients with week 104 PET scans from MR and SR OLE studies. Exploratory analyses included comparing clinical endpoint trajectories in patients with higher versus lower levels of PET amyloid reductions based on median split using MMRM (adjusted for baseline clinical endpoint value), and fitting a newly developed joint model for the simultaneous evaluation of biomarker and clinical endpoint longitudinal data.(4)

Results: Large mean amyloid reductions (-38 centiloids [SD 38.1] at week 52 [N=67] and -59 centiloids [SD 35.3] at week 104 [N=39]), often to below the amyloid positivity threshold, were observed. At week 104, point estimates indicated 17–46% less clinical decline in the subgroup with larger (> median) PET reductions versus those with smaller reductions. Similar directional trends were observed across all analysis methods and clinical endpoints.

Conclusion: Larger amyloid reductions at week 104 were associated with a trend toward less decline in clinical scales. Given the limited sample size and absence of a placebo arm, clinical outcome data should be interpreted with caution. However these data, together with the favorable safety profile observed at these dose levels, support the rationale for further investigation of the clinical efficacy of gantenerumab and 2 ongoing pivotal PhIII trials in patients with early (prodromal-to-mild) AD (GRADUATE I [NCT03444870]; GRADUATE II [NCT03443973]). 1.Klein, et al. CTAD 2018 2.Ostrowitzki S, et al. Alzheimers Res Ther 2017 3.Klunk WE, et al. Alzheimers Dem 2015 4.Wang G,et al. AlzheimersDem2018

Towards Dementia Friendly Emergency Departments: A Mixed Method Exploratory Study Identifying Opportunities to Improve the Quality and Safety of Care for People with Dementia in Emergency Departments

Courtney Shaw1, Gerrard Armitage2, Andrea Capstick3

1SE Research Centre; 2University of Bradford/Bradford District Care Trust; 3University of Bradford

Background/Objectives: People living with dementia (PLWD) are frequent users of Emergency Departments (ED’s). They tend to have complex care needs as a result of multi-morbidities, cognitive impairments and enhanced need for social support. Despite the prevalence of dementia in ED patients, the physical environment and care processes are typically not designed to meet their holistic needs. The objective of this project was to create a model of dementia friendly emergency care

Methods: This is a mixed and multiple methods study which used an iterative and sequential design to present a holistic evaluation of the current experiences of the key parties—patients, caregivers, and ED staff involved in receiving and providing
Background/Objectives: Dementia is a growing concern for Indigenous people worldwide. Age and other factors including high rates of multiple, complex health conditions at a younger age of onset and a combination of social, historical and colonial factors have led to projections of increased dementia in First Nations populations. Yet early detection of dementia in Indigenous populations remains challenging as current cognitive assessment tools are shown to be less reliable when used in these populations. The need for culturally appropriate clinical measures for dementia was identified by Indigenous community members and health care providers in Ontario, Saskatchewan and Alberta as a priority.

Methods: The Canadian Indigenous Cognitive Assessment (CICA) tool is a culturally-informed cognitive assessment tool that was adapted by Anishinaabe First Nations communities on Manitoulin Island, Ontario. The CICA was validated over a period of several years using a multi-phase approach that included adaptation, translation, piloting, reliability and validity testing. The CICA was successfully validated in summer 2018 and takes approximately 15 minutes to complete, assesses 11 domains of cognition and provides a final score out of a possible 39 points. This study reports the inter-rater reliability and criterion validity of the newly developed CICA.

Results: The CICA demonstrated strong reliability (ICC = 0.95 (0.85,0.98)) and validity. The ideal cut-point to identify likely cases of dementia was a score of less than or equal to 34, for which the sensitivity was 100%, specificity was 85%, likelihood ratio plus (LR+) was 6.5 and the AUC was 0.98 (95%CI: 0.94 to 1.00). The results indicated a range of domain discriminability (Partial R-square range = 0.04 – 0.57). Two cognitive domains alone accounted for 71% of the variance in dementia status.

Conclusion: The CICA is the first tool of its kind in Canada. The successful validation of the CICA tool on Manitoulin Island marks a significant step forward in the broader effort to provide culturally-safe health care services for Indigenous populations. The implications of the CICA for improved detection of cognitive impairment and dementia among Indigenous populations, culturally-safe pathways to formal healthcare, dementia surveillance, resource allocation and policy and planning are substantial.

Can a Group Exergame Intervention Impact Balance, Movement Confidence, and Cognitive Function in People with Dementia or Mild Cognitive Impairment?

Erica Dove¹, Arlene Astell²

¹University of Toronto; ²Toronto Rehabilitation Institute

Background/Objectives: Participation in exercise programs can benefit people with cognitive impairment (PCI; e.g. dementia). However, many exercise programs offered to...
this population are passive, unengaging, and repetitive, resulting in poor engagement and long-term adherence. The potential of integrating video games and exercise programs (i.e. ‘exergame’ programs) is being explored to encourage exercise participation among PCI. However, the impacts on key variables including balance, movement confidence, and cognitive function have yet to be determined. This study aims to examine the impacts of a group exergame intervention (Xbox Kinect bowling) for PCI on balance, movement confidence, and cognitive function.

Methods: This within-participants design includes measurement at pre- and post-intervention. Twenty-four PCI are being recruited from two adult day programs in Durham Region, ON. At pre-test, participants will complete a demographic survey, the Mini Balance Evaluation Systems Test (Mini-BEST), and the Montreal Cognitive Assessment (MoCA). Participants will play an Xbox Kinect bowling game in a group setting, twice per week for ten weeks (20 sessions). Participants will be video recorded at three time points (start, middle, and end) to capture physical indicators of movement confidence (e.g. fluency of motion, visual focus, hesitation) during the intervention. At post-test, the Mini-BEST and MoCA will be repeated.

Results: Quantitative data collected through the Mini-BEST, coded video recordings, and the MoCA will be compared from pre- to post-test using paired t-tests. An ANCOVA with post hoc analyses will also be performed to account for covariates (e.g. number of intervention sessions attended).

Conclusion: The exergame intervention has the potential to positively impact participants' physical function, specifically balance (score on the Mini-BEST) and movement confidence (coded from video recordings). This will confirm the feasibility and potential benefits of using MBT to deliver video game-based exercise interventions to PCI. There is also potential for the MBT intervention to positively impact cognitive function of PCI (as measured through MoCA score). This work can be used as the basis for developing both specific software and future video game-based exercise programs for PCI.

Use of Medium Chain Triglyceride (MCT) Oil in Subjects with Alzheimer’s Disease: A Randomized Double-Blind Placebo Cross Over Study, with an Open Label Extension

Angela Juby1, Diana Mager1, Christopher Davis1, David Jay2, Toni Blackburn3

1University of Alberta; 2Grant MacEwan University; 3Alberta Health Services

Background/Objectives: Cerebral glucose metabolism is impaired in subjects with Alzheimer’s disease (AD). Under conditions of low glucose availability the brain has the capacity to use ketones as an alternative energy source. The usual source of ketones is break down of stored triglycerides, and occurs in fasting or low calorie intake states. This endogenous ketone production has been shown to be helpful in other neurological diseases, such as epilepsy, but not in AD. Practically, it is difficult to reduce calories sufficiently for an endogenous ketogenic response. Medium chain triglycerides (MCT) are known to be an exogenous (dietary) source of ketones.

Methods: This study is to evaluate the impact, if any, of MCT oil supplementation in AD subjects. It is a six month randomised, double blind, placebo, cross over study, with 6 month open label extension evaluating MCT oil versus olive oil on cognition, behavior and activities of daily living function in community dwelling AD subjects. One month dose titration (15mls-30mls-45mls or maximum tolerated dose (MTD) daily) followed by 3 months of MTD, occurred in the cross-over phase. This was followed by 6 months of open label extension of MTD MCT oil. Subjects were allowed to continue all medications including cholinesterase inhibitors, memantine and antidepressants provided the doses remained stable during the study. This study was approved by the Health Canada (HC) and the local Ethics Board. Patients with concomitant Diabetes were not included as per HC requirement.

Results: Twenty AD subjects completed the first 6 months, and 19 completed the full 15 months. Participant’s age ranged from 54–84yrs (average age of 72.6yrs), and included 11 men and 9 women. 70% had College/University education. Baseline Mini Mental status Examination (MMSE) score 22.6/30 (10–29). Montreal Cognitive Assessment (MoCA) 15.6/30 (4–30). Baseline Cognigram® Part 1 ranged from 65–106, Part 2 from 48–107. There were no significant differences between the two groups at baseline. Apo E4 status was homozygous in one subject, and heterozygous in nine (50% overall positive ApoE4). Average MCT oil consumption was 1.8 tablespoons daily (25.2g, 234kcal). There was individual variability in MMSE and MoCA over the course of the study, but most remained stable or improved. Four (20%) declined more rapidly than expected (based on their initial MMSE). There was no difference in average MCT intake in “decliners”. No change in serum lipids or % body fat occurred.

Conclusion: Only recently has attention been drawn to the use of MCT oil as a source of ketones for AD subjects, with the hope that this may improve their brain metabolism and thereby cognitive function. The objective of this study is to evaluate the impact, if any, of MCT oil on cognition, activities of daily living (ADLs) and behavior in AD subjects. Preliminary analysis shows stabilization in cognition. This is not what would have been expected in these established AD patients. The differences between responders and decliners is being evaluated further.